GlassScriptPhysician profile
David Keith Holmes
NPI 1780046052
$2,941.26
in general payments reported to CMS, 2019-2025
28 companies · $531 in 2025
The $531 reported for 2025 was more than what 82% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.48 · 2020: $132 · 2021: $546 · 2022: $647 · 2023: $614 · 2024: $447 · 2025: $531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,578 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,577.90 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $677.36 | 2020-2025 | |
| Mayne Pharma Commercial LLC | $568.52 | 2021-2025 | |
| Exeltis, USA INC. | $361.79 | 2021-2025 | Slynd |
| Astellas Pharma US INC | $210.51 | 2024-2025 | Veozah |
| Baxter Healthcare | $174.81 | 2022-2024 | Starling System |
| Biogen, INC. | $156.39 | 2024-2025 | Zurzuvae |
| Therapeuticsmd, INC. | $83.30 | 2020-2022 | |
| Sumitomo Pharma America, INC. | $74.67 | 2023-2025 | Gemtesa, Myfembree |
| Agile Therapeutics, INC. | $58.38 | 2021-2022 | |
| Mylan Pharmaceuticals INC. | $54.52 | 2020-2021 | |
| Pfizer INC. | $45.81 | 2023-2025 | |
| Shield Therapeutics INC | $45.19 | 2025 | |
| Evofem Biosciences, INC. | $41.14 | 2021-2022 | |
| Avion Pharmaceuticals | $40.48 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.81 | 2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $32.08 | 2024 | Intrarosa, Femring |
| Novo Nordisk INC | $30.23 | 2022-2023 | Wegovy, Saxenda |
| Sanofi Pasteur INC. | $29.51 | 2024 | |
| Myovant Sciences INC. | $29.09 | 2021-2022 | |
| Daiichi Sankyo INC. | $28.38 | 2024 | Injectafer |
| Currax Pharmaceuticals LLC | $26.71 | 2020-2021 | |
| Ascend Therapeutics US, LLC | $24.91 | 2023 | |
| Avanos Medical | $24.48 | 2019 | |
| Scynexis, INC. | $19.46 | 2022 | |
| Alexion Pharmaceuticals, INC. | $16.80 | 2022 | |
| Optumhealth Care Solutions, LLC | $16.74 | 2025 | Vivify Health Care Team Portal 001, Eitan Medical |
| Medline Industries LP | $15.94 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $15.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Holmes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.